同位素2024,Vol.37Issue(2) :185-194.DOI:10.7538/tws.2023.youxian.067

无载体镥-177分离技术研究进展

No-Carrier-Added Lutetium-177 Separation Technology Status

李波 胡映江 吴建荣 王磊 陈云明 张劲松 罗宁
同位素2024,Vol.37Issue(2) :185-194.DOI:10.7538/tws.2023.youxian.067

无载体镥-177分离技术研究进展

No-Carrier-Added Lutetium-177 Separation Technology Status

李波 1胡映江 1吴建荣 1王磊 1陈云明 1张劲松 1罗宁1
扫码查看

作者信息

  • 1. 中国核动力研究设计院,成都 610213;同位素及药物国家工程研究中心,成都 610213;四川省放射性同位素工程技术研究中心,成都 610213
  • 折叠

摘要

医用同位素是核医学诊疗的物质基础.利用核医学技术对恶性肿瘤、心脑血管、神经退行性疾病等重大疾病进行诊断与治疗具有不可替代的优势.镥-177(177Lu)具有优异的核物理和化学性质,近年来,欧美发达国家已将其广泛应用于靶向核素治疗研究及临床应用,其标记物对神经内分泌肿瘤、前列腺癌等肿瘤的诊断和治疗展示出良好效果.177Lu已被公认为是目前最具前景和市场活力的靶向放射性诊疗一体化核素之一,预计未来全球对177Lu的需求呈爆发式增长.本研究综述了177Lu的制备原理、国内外分离工艺研究现状、未来市场需求和应用前景.

Abstract

Medical isotopes are the substantial basis of the diagnostic and therapeutic nuclear medicine.There are irreplaceable advantages for utilizing the nuclear medical technology to diagnose and treat the malignant tumors,cardiovascular and cerebrovascular diseases,neurodegenerative diseases and other major diseases.Lutetium-177(177Lu)has excellent nuclear physical and chemical properties.In recent years,177Lu has been widely used in the research and clinical application of targeted nuclide therapy in the western developed countries,and the radio-labeled compounds have showed the good effects in the diagnosis and treatment of tumors,including neuroendocrine tumors,prostate cancer,metastatic disease in bone and etc.177Lu has been recognized as one of the most promising and dynamic economical theranostic targeted medical radio-isotopesand the global demand for 177Lu can be expected to grow explosively in the future.In this text,the preparation principle of 177Lu and current research status of 177Lu separation technology domestically or internationally,the future market demand and the application prospect were briefly introduced.

关键词

中子辐照/有载体177Lu/无载体177Lu/放化分离/靶向放射性核素治疗

Key words

neutron irradiation/carrier-added(CA)177Lu/no-carrier-added 177Lu/radiochemical separation/targeted radionuclide therapy

引用本文复制引用

出版年

2024
同位素
中国核学会同位素分会

同位素

CSTPCD
影响因子:0.405
ISSN:1000-7512
参考文献量35
段落导航相关论文